Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Executive Summary

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4
Advertisement

Related Content

Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival
Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival
Progression-Free Survival Must Be Tied To Survival For Oncologic Approval
Progression-Free Survival Must Be Tied To Survival For Oncologic Approval
Prostate Cancer Trial Composite PSA/Bone Scan Endpoint Suggested By FDA
Prostate Cancer Trial Composite PSA/Bone Scan Endpoint Suggested By FDA
Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials
Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Advertisement
UsernamePublicRestriction

Register

PS043963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel